There are 2789 resources available
Discussion 517MO and 518MO
Presenter: Richard Schlenk
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
Discussion 519MO and 520MO
Presenter: Richard Baird
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
Discussion 343MO and 344MO
Presenter: Enrico Franceschi
Session: Mini oral session - CNS tumours
Resources:
Slides
Webcast
LBA13 - Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
Presenter: Nadia Harbeck
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial
Presenter: Carme Balaña
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial
Presenter: Nader Sanai
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Presenter: Giampaolo Bianchini
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
120MO - Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Presenter: Aranzazu Fernandez-Martinez
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Consistent with regimens appropriate for initial treatment of metastatic disease
Presenter: Federico Cappuzzo
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast